[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-333006-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-333006-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-stem-cells-in-meningiomas-novel-insights-and-therapeutic-implications-research-review","Cancer stem cells in meningiomas: novel insights and therapeutic implications - Research review","","Meningiomas (MGs), arising from meningothelial cells of the dura mater, represent a major share of primary CNS tumours. Even with treatment advances, malignant meningioma (MMG) management remains difficult due to constraints in diagnosis, surgery, and resection. Cancer stem cells (CSCs) drive self-renewal, differentiation, metastasis, and therapy resistance, making CSC biomarkers central to precise malignancy assessment. The review synthesizes CSC markers and molecular targets, outlining combination and pathway-based strategies to improve prognosis and durability of tumour regression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-stem-cells-in-meningiomas-novel-insights-and-therapeutic-implications-research-review/333006/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-stem-cells-in-meningiomas-novel-insights-and-therapeutic-implications-research-review/333006.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is managing malignant meningioma (MMG) challenging?","Question",{"text":63,"@type":64},"MMG is difficult to manage because diagnostic approaches and surgical or resection options have limitations, making it hard to define grade and growth potential accurately and to achieve complete removal safely.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do cancer stem cells (CSCs) play in meningiomas?",{"text":68,"@type":64},"CSCs are tumour subpopulations with self-renewal and differentiation capabilities. They are linked to tumour growth, metastasis, and treatment resistance, so identifying CSC markers can improve malignancy evaluation and personalized care.",{"name":70,"@type":61,"acceptedAnswer":71},"Which molecular targets and strategies are discussed for therapeutic development?",{"text":72,"@type":64},"The review highlights CSC-related biomarkers such as Oct-4, Sox2, NANOG, and CD133, and discusses pathway-focused approaches involving NOTCH and hedgehog. Combination therapies and CRISPR/Cas9-based meningioma models are also presented as promising directions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},333006,1790194245,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Clinical and Translational Oncology (2025) 27:1438–1459  \n[https://doi.org/10.1007/s12094-024-03728-6](https://doi.org/10.1007/s12094-024-03728-6)  \nCancer stem cells in meningiomas: novel insights and therapeutic implications  \nWireko Andrew Awuah1 · Adam Ben‑Jaafar2 · Simran Karkhanis3 · Princess Afia Nkrumah‑Boateng4 · Jonathan Sing Huk Kong5 · Krishitha Meenu Mannan6 · Vallabh Shet7 · Shahzeb Imran6 · Matan Bone8 · Allswell Naa Adjeley Boye4 · Sruthi Ranganathan9 · Muhammad Hamza Shah3 · Toufik Abdul‑Rahman1 · Oday Atallah10  \nReceived: 21 August 2024 / Accepted: 9 September 2024 / Published online: 24 September 2024 © The Author(s) 2024  \nAbstract  \nMeningiomas (MGs), which arise from meningothelial cells of the dura mater, represent a significant proportion of primary tumours of the central nervous system (CNS) . Despite advances in treatment, the management of malignant meningioma (MMG) remains challenging due to diagnostic, surgical, and resection limitations. Cancer stem cells (CSCs), a subpopulation within tumours capable of self-renewal and differentiation, are highlighted as key markers of tumour growth, metastasis, and treatment resistance. Identifying additional CSC-related markers enhances the precision of malignancy evaluations, enabling advancements in personalised medicine. The review discusses key CSC biomarkers that are associated with high levels of expression, aggressive tumour behaviour, and poor outcomes. Recent molecular research has identified CSC-related biomarkers, including Oct-4, Sox2, NANOG, and CD133, which help maintain cellular renewal, proliferation, and drug resistance in MGs. This study highlights new therapeutic strategies that could improve patient prognosis with more durable tumour regression. The use of combination therapies, such as hydroxyurea alongside diltiazem, suggests more efficient and effective MG management compared to monotherapy. Signalling pathways such as NOTCH and hedgehog also offer additional avenues for therapeutic development. CRISPR/Cas9 technology has also been employed to create meningioma models, uncovering pathways related to cell growth and proliferation. Since the efficacy of traditional therapies is limited in most cases due to resistance mechanisms in CSCs, further studies on the biology of CSCs are warranted to develop therapeutic interventions that are likely to be effective in MG. Consequently, improved diagnostic approaches may lead to personalised treatment plans tailored to the specific needs of each patient.  \nKeywords Meningioma stem cells · Meningioma · Neuro-oncology · Neuro-genetics  \nAbbreviations  \nCNS Central nervous system  \nMMGs Malignant meningiomas  \nMGs Meningiomas  \nMRI Magnetic resonance imaging  \nCSCs Cancer stem cells  \nNF2 Neurofibromatosis 2  \nKLF4 Krüppel-like factor 4  \nMEN1 Multiple endocrine neoplasia type 1  \nAML Acute myeloid leukaemia  \nHATs Histone acetylases  \nTRAF7 Tumour necrosis receptor-associated factor ABC Adenosine-triphosphate-binding cassette  \nTME Tumour microenvironment  \nExtended author information available on the last page of the article  \nMgSCs HH  \nSHH  \nIHH  \nPTCH1  \nGFAP  \nCSF1 RNA-seq PD-L1 MDSCs Tregs MMR  \nIDO1  \nHU  \nPRRT  \nVPA  \nMeningioma stem cells Hedgehog  \nSonic hedgehog Indian hedgehog Patched receptor 1  \nGlial fibrillary acidic protein Colony-stimulating factor 1  \nRibonucleic acid sequencing Programmed death-ligand 1  \nMyeloid-derived suppressor cells Regulatory T cells  \nMismatch repair Indoleamine 2,3-dioxygenase 1 Hydroxyurea  \nPeptide receptor radionuclide therapy Valproic acid  \nMgACs P-cdc2 EMBASE MEDLINE  \nCRISPR  \nWHO  \nCBTRUS  \nDNA  \nDNMT  \nVEGF  \nECM  \nTNF  \nNSC  \nESCs  \nOct-4  \nSox2  \nNestin  \nSMO  \nGli1  \nCRISPR  \nCas9  \nmTOR  \nGB  \nMeningioma-adherent cells Phosphorylated cdc2 Excerpta Medica Database  \nMedical literature analysis and retrieval system online  \nClustered regularly interspaced short palindromic repeats  \nWorld Health Organisation  \nCentral Brain Tumour Registry of th","cbCaiprhnSFu1y5L","https://ap.wps.com/l/cbCaiprhnSFu1y5L","pdf",1646988,22,"English","# Abstract\n## Background\n## Diagnostic and treatment challenges\n## Chemotherapy options and knowledge gaps","[{\"question\":\"Why is managing malignant meningioma (MMG) challenging?\",\"answer\":\"MMG is difficult to manage because diagnostic approaches and surgical or resection options have limitations, making it hard to define grade and growth potential accurately and to achieve complete removal safely.\"},{\"question\":\"What role do cancer stem cells (CSCs) play in meningiomas?\",\"answer\":\"CSCs are tumour subpopulations with self-renewal and differentiation capabilities. They are linked to tumour growth, metastasis, and treatment resistance, so identifying CSC markers can improve malignancy evaluation and personalized care.\"},{\"question\":\"Which molecular targets and strategies are discussed for therapeutic development?\",\"answer\":\"The review highlights CSC-related biomarkers such as Oct-4, Sox2, NANOG, and CD133, and discusses pathway-focused approaches involving NOTCH and hedgehog. Combination therapies and CRISPR/Cas9-based meningioma models are also presented as promising directions.\"}]","Cancer stem cells in meningiomas: novel insights and therapeutic implications - Research review | PDF",1790000334,55]